122 related articles for article (PubMed ID: 2276100)
1. CQA 206-291 in Parkinson's disease: an acute single escalating dosage study.
Lang AE; Riley DE; Vachon L; Lataste X
Can J Neurol Sci; 1990 Nov; 17(4):416-9. PubMed ID: 2276100
[TBL] [Abstract][Full Text] [Related]
2. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of pergolide in Parkinson's disease].
Gonce M; Delwaide PJ
Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
Schneider E; Hubener K; Fischer PA
Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
[TBL] [Abstract][Full Text] [Related]
5. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
6. Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
Rascol A; Montastruc JL; Rascol O; Senard JM
Clin Neuropharmacol; 1986; 9(2):146-52. PubMed ID: 3708600
[TBL] [Abstract][Full Text] [Related]
7. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Marsden CD
Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
[TBL] [Abstract][Full Text] [Related]
9. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
Pfeiffer RF; Wilken K; Glaeske C
Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
[TBL] [Abstract][Full Text] [Related]
10. Pergolide in the treatment of Parkinson's disease.
Quinn NP; Lang AE; Thompson C; Brincat S; Marsden CD; Parkes JD
Adv Neurol; 1984; 40():509-13. PubMed ID: 6695628
[No Abstract] [Full Text] [Related]
11. Mesulergine and pergolide in previously untreated Parkinson's disease.
Wright A; Lees AJ; Stern GM
J Neurol Neurosurg Psychiatry; 1987 Apr; 50(4):482-4. PubMed ID: 3585362
[TBL] [Abstract][Full Text] [Related]
12. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Grosset K; Needleman F; Macphee G; Grosset D
Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
[TBL] [Abstract][Full Text] [Related]
13. Mesulergine in early Parkinson's disease: a double blind controlled trial.
Dupont E; Mikkelsen B; Jakobsen J
J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):390-5. PubMed ID: 3517235
[TBL] [Abstract][Full Text] [Related]
14. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
[TBL] [Abstract][Full Text] [Related]
15. Placebo-controlled study of mesulergine in Parkinson's disease.
Jankovic J; Orman J; Jansson B
Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
[TBL] [Abstract][Full Text] [Related]
16. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
[TBL] [Abstract][Full Text] [Related]
17. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
Goetz CG; Tanner CM; Glantz RH; Klawans HL
Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
[TBL] [Abstract][Full Text] [Related]
18. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy.
Pal S; Bhattacharya KF; Agapito C; Chaudhuri KR
J Neural Transm (Vienna); 2001; 108(1):71-7. PubMed ID: 11261748
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study.
Utsumi H;
Acta Med Okayama; 2012; 66(2):163-70. PubMed ID: 22525474
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
Bachmann CG; Zapf A; Brunner E; Trenkwalder C
Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
